These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
155 related articles for article (PubMed ID: 11964918)
21. Antimicrobial susceptibilities of Streptococcus pneumoniae isolated from adult patients with community-acquired pneumonia in Japan. Ishida T; Maniwa K; Kagioka H; Hirabayashi M; Onaru K; Tomioka H; Hayashi M; Tomii K; Gohma I; Ito Y; Hirai T; Ito I; Mishima M Respirology; 2008 Mar; 13(2):240-6. PubMed ID: 18339022 [TBL] [Abstract][Full Text] [Related]
22. [Antimicrobial susceptibility of community-acquired respiratory tract pathogens isolated from adults in China during 2009 and 2010]. Wang H; Liu YL; Chen MJ; Xu YC; Sun HL; Yang QW; Hu YJ; Cao B; Chu YZ; Liu Y; Zhang R; Yu YS; Sun ZY; Zhuo C; Ni YX; Hu BJ Zhonghua Jie He He Hu Xi Za Zhi; 2012 Feb; 35(2):113-9. PubMed ID: 22455967 [TBL] [Abstract][Full Text] [Related]
23. Emergence of antimicrobial resistance in community-acquired pulmonary pathogens. Cunha BA; Shea KW Semin Respir Infect; 1998 Mar; 13(1):43-53. PubMed ID: 9543475 [TBL] [Abstract][Full Text] [Related]
24. [Acute community-acquired pneumonia. A review of clinical trials]. Chidiac C Med Mal Infect; 2006; 36(11-12):650-66. PubMed ID: 16876363 [TBL] [Abstract][Full Text] [Related]
25. Clinical efficacy of newer agents in short-duration therapy for community-acquired pneumonia. File TM Clin Infect Dis; 2004 Sep; 39 Suppl 3():S159-64. PubMed ID: 15546111 [TBL] [Abstract][Full Text] [Related]
26. Doxycycline use for community-acquired pneumonia: contemporary in vitro spectrum of activity against Streptococcus pneumoniae (1999-2002). Jones RN; Sader HS; Fritsche TR Diagn Microbiol Infect Dis; 2004 Jun; 49(2):147-9. PubMed ID: 15183865 [TBL] [Abstract][Full Text] [Related]
28. The clinical relevance of in-vitro resistance to penicillin, ampicillin, amoxycillin and alternative agents, for the treatment of community-acquired pneumonia caused by Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis. Klugman KP J Antimicrob Chemother; 1996 Jul; 38 Suppl A():133-40. PubMed ID: 8858479 [TBL] [Abstract][Full Text] [Related]
29. The comparative development of elevated resistance to macrolides in community-acquired pneumonia caused by Streptococcus pneumoniae. Yayan J Drug Des Devel Ther; 2014; 8():1733-43. PubMed ID: 25336917 [TBL] [Abstract][Full Text] [Related]
30. Antibiotic susceptibility according to genotype of penicillin-binding protein and macrolide resistance genes, and serotype of Streptococcus pneumoniae isolates from community-acquired pneumonia in children. Chiba N; Kobayashi R; Hasegawa K; Morozumi M; Nakayama E; Tajima T; Iwata S; Ubukata K; J Antimicrob Chemother; 2005 Oct; 56(4):756-60. PubMed ID: 16131518 [TBL] [Abstract][Full Text] [Related]
31. Community-acquired respiratory tract infections caused by resistant pneumococci: clinical and bacteriological efficacy of the ketolide telithromycin. Fogarty CM; Kohno S; Buchanan P; Aubier M; Baz M J Antimicrob Chemother; 2003 Apr; 51(4):947-55. PubMed ID: 12654763 [TBL] [Abstract][Full Text] [Related]
32. Clinical impact of antimicrobial resistance in humans. Collignon P Rev Sci Tech; 2012 Apr; 31(1):211-20. PubMed ID: 22849277 [TBL] [Abstract][Full Text] [Related]
33. Evolving trends in Streptococcus pneumoniae resistance: implications for therapy of community-acquired bacterial pneumonia. Jones RN; Jacobs MR; Sader HS Int J Antimicrob Agents; 2010 Sep; 36(3):197-204. PubMed ID: 20558045 [TBL] [Abstract][Full Text] [Related]
34. The clinical significance of macrolide-resistant Streptococcus pneumoniae: it's all relative. Nuermberger E; Bishai WR Clin Infect Dis; 2004 Jan; 38(1):99-103. PubMed ID: 14679455 [TBL] [Abstract][Full Text] [Related]
35. Mechanisms, molecular and sero-epidemiology of antimicrobial resistance in bacterial respiratory pathogens isolated from Japanese children. Sunakawa K; Farrell DJ Ann Clin Microbiol Antimicrob; 2007 Aug; 6():7. PubMed ID: 17697316 [TBL] [Abstract][Full Text] [Related]
37. Non-susceptibility trends and serotype distributions among Streptococcus pneumoniae from community-acquired respiratory tract infections and from bacteraemias in the UK and Ireland, 1999 to 2007. Farrell DJ; Felmingham D; Shackcloth J; Williams L; Maher K; Hope R; Livermore DM; George RC; Brick G; Martin S; Reynolds R; J Antimicrob Chemother; 2008 Nov; 62 Suppl 2():ii87-95. PubMed ID: 18819983 [TBL] [Abstract][Full Text] [Related]
38. The clinical impact of macrolide resistance in pneumococcal respiratory infections. Garau J Int J Antimicrob Agents; 2001; 18 Suppl 1():S33-8. PubMed ID: 11574193 [TBL] [Abstract][Full Text] [Related]
39. A clinical solution to antimicrobial resistance in community-acquired pneumonia: narrowing the spectrum of antimicrobial therapy: comment on "Current and potential usefulness of pneumococcal urinary antigen detection in hospitalized patients with community-acquired pneumonia to guide antimicrobial therapy". Yu VL Arch Intern Med; 2011 Jan; 171(2):172-3. PubMed ID: 21263107 [No Abstract] [Full Text] [Related]
40. The hidden impact of antibacterial resistance in respiratory tract infection. Clinical failures: the tip of the iceberg? Garau J Respir Med; 2001 Jun; 95 Suppl A():S5-11; discussion S26-7. PubMed ID: 11419672 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]